Editorial: The year in hyperlipidaemia
No abstract available (Source: Current Opinion in Cardiology)
Source: Current Opinion in Cardiology - June 10, 2021 Category: Cardiology Tags: LIPIDS AND EMERGING RISK FACTORS: Edited by Dimitri P. Mikhailidis and Anthony S. Wierzbicki Source Type: research
Interactions of hypertension, obesity, left ventricular hypertrophy, and heart failure
Purpose of review
Hypertension (HTN) and obesity are major risk factors for cardiac remodeling and dysfunction, leading to left ventricular hypertrophy (LVH) and heart failure (HF). In this review, we discuss the complex mechanisms and effects of HTN and obesity, and their treatments in LVH, ventricular function, and HF.
Recent findings
Obesity and HTN impact the heart through overlapping neurohormonal pathways. However, the relationship between obesity and cardiomyopathy is more complex, and additional metabolic and hemodynamic pathways seem to contribute to cardiac dysfunction in these patients. Weight loss an...
Source: Current Opinion in Cardiology - June 10, 2021 Category: Cardiology Tags: HYPERTENSION: Edited by Hector O. Ventura and Carl J. Lavie Source Type: research
Renal interventions in the management of hypertension
Purpose of review
In the present comprehensive review, we describe the pathophysiology, indications, and evidence for both renal artery stenting and renal artery denervation. We also discuss the procedural techniques, risks, benefits, and future directions of renal intervention in the management of hypertension (HTN).
Recent findings
Hemodynamic confirmation of lesion severity in severe renal artery stenosis is a resting or hyperemic translesional systolic gradient>20, resting or hyperemic mean translesional gradient>10 and/or renal fractional flow reserve (Source: Current Opinion in Cardiology)
Source: Current Opinion in Cardiology - June 10, 2021 Category: Cardiology Tags: HYPERTENSION: Edited by Hector O. Ventura and Carl J. Lavie Source Type: research
Global interventions in hypertension: new and emerging concepts
Purpose of review
Hypertension (HTN) is the most prevalent risk factor for cardiovascular disease (CVD) worldwide, affecting 1.39 billion people. This review discusses recent literature regarding the global burden of HTN and emerging concepts in prevalence, treatment, and control in different regions around the globe.
Recent findings
Community-based interventions and telemedicine may be useful in increasing access to care and identifying/assisting patients with HTN, especially in populations with geographical and economic barriers to healthcare. Home blood pressure monitoring is beneficial for HTN control in div...
Source: Current Opinion in Cardiology - June 10, 2021 Category: Cardiology Tags: HYPERTENSION: Edited by Hector O. Ventura and Carl J. Lavie Source Type: research
New findings bearing on the prevention, detection and management of high blood pressure
Purpose of review
Hypertension is the foremost risk factor for cardiovascular disease (CVD) and death. This review highlights recent findings that apply to the prevention, detection, and management of high blood pressure (BP), in the context of the 2017 American College of Cardiology/American Heart Association BP guideline.
Recent findings
Several new findings on the association of BP measurement with CVD outcomes are now available. (1) Beginning with a systolic BP (SBP) as low as 90 mm Hg, coronary artery calcium deposition and the risk of incident atherosclerotic CVD (ASCVD) increased in stepwise fashion wit...
Source: Current Opinion in Cardiology - June 10, 2021 Category: Cardiology Tags: HYPERTENSION: Edited by Hector O. Ventura and Carl J. Lavie Source Type: research
Medical management of resistant hypertension: the role of sodium-glucose cotransporter 2 inhibitors (SGLT2i)
Purpose of review
Controlling hypertension to the desired target is commonly unsuccessful and requires multi-drug regimen, which can lead to undesirable side effects. Resistant hypertension (RH) is more cumbersome to deal with and has robust morbidity and mortality burden even with current multiple medical options. Herein, we review the literature for the potential role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) as a treatment option for hypertension and RH.
Recent findings
With more recent randomized controlled trials (RCTs), SGLT2i have gained more recognition for their renal and cardiovascular prot...
Source: Current Opinion in Cardiology - June 10, 2021 Category: Cardiology Tags: HYPERTENSION: Edited by Hector O. Ventura and Carl J. Lavie Source Type: research
Management of hypertension in heart failure with preserved ejection fraction: is there a blood pressure goal?
Purpose of review
Hypertension remains a leading risk factor for heart failure with preserved ejection fraction (HFpEF), and elevated blood pressure (BP) portends an adverse prognosis in patients with established HFpEF. We summarize current evidence for mechanisms linking hypertension to HFpEF and management of hypertension in HFpEF.
Recent findings
Data suggest a complex, multifactorial pathophysiology driving the association between hypertension and HFpEF, including left ventricular hypertrophy, diastolic dysfunction, atrial dysfunction, coronary microvascular disease, endothelial dysfunction, myocardial injur...
Source: Current Opinion in Cardiology - June 10, 2021 Category: Cardiology Tags: HYPERTENSION: Edited by Hector O. Ventura and Carl J. Lavie Source Type: research
Tailoring the management of hypertension to comorbidities
Purpose of review
In this article, we review the most current evidence for initiation and maintenance of various antihypertension (HTN) drug classes, including other misconceptions with respect to common comorbidities in patients with HTN.
Recent findings
Although the currently available anti-HTN agents have broad applicability in treating HTN, additional agents, such as angiotensin receptor-neprilysin inhibitors and novel nonsteroidal mineralocorticoid antagonists, have recently gained clinical significance. In addition, there have been some anecdotal concerns regarding the adverse effects, indications, and ris...
Source: Current Opinion in Cardiology - June 10, 2021 Category: Cardiology Tags: HYPERTENSION: Edited by Hector O. Ventura and Carl J. Lavie Source Type: research
New aspects in the management of hypertension in the digital era
Purpose of review
Hypertension (HTN) is the most common chronic disease impacting over half the US adult population. Our current office-based model of care is failing in its ability to control blood pressure (BP) as only 44% of adult US hypertensives are achieving minimal levels of BP control ( (Source: Current Opinion in Cardiology)
Source: Current Opinion in Cardiology - June 10, 2021 Category: Cardiology Tags: HYPERTENSION: Edited by Hector O. Ventura and Carl J. Lavie Source Type: research
Editorial: The burden of hypertension and its management
No abstract available (Source: Current Opinion in Cardiology)
Source: Current Opinion in Cardiology - June 10, 2021 Category: Cardiology Tags: HYPERTENSION: Edited by Hector O. Ventura and Carl J. Lavie Source Type: research
Antiplatelet therapy in percutaneous coronary intervention: latest evidence from randomized controlled trials
Purpose of review
Antiplatelet therapy is key to reduce systemic and local thrombotic events among patients undergoing percutaneous coronary interventions (PCI). Antiplatelet treatment regimens have been subject to continuous changes over the years, with a dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 inhibitor representing the cornerstone of treatment in these patients.
Recent findings
The need for less aggressive antithrombotic drugs to prevent local ischemic events with newer generation drug-eluting stent together with the increased understanding of the prognostic relevance of bleeding e...
Source: Current Opinion in Cardiology - June 10, 2021 Category: Cardiology Tags: CLINICAL TRIALS: Edited by Neal S. Kleiman Source Type: research
Transcatheter mitral valve replacement: an update
Purpose of review
A significant number of patients with mitral valve disease are at high to prohibitive risk for surgical repair or replacement. Transcatheter mitral valve interventions have evolved over the last few years. We review the recent growing evidence on transcatheter mitral valve replacement (TMVR).
Recent findings
Tendyne is the first TMVR device commercially approved in Europe. All TMVR systems remain under investigation in the United States. Several early studies have reported the feasibility and safety outcomes for TMVR implanted via transapical or transseptal approach. TMVR using balloon expandab...
Source: Current Opinion in Cardiology - June 10, 2021 Category: Cardiology Tags: CLINICAL TRIALS: Edited by Neal S. Kleiman Source Type: research
Temporary mechanical circulatory support devices: updates from recent studies
Purpose of review
Over the past several years, the role of short-term mechanical circulatory support (MCS) devices has become the dominant focus in efforts to improve outcomes in patients with cardiogenic shock (CS). Alongside these efforts, temporary MCS devices have been increasingly used to support patients prior to cardiac surgery, during high-risk percutaneous coronary intervention, awaiting cardiac transplantation, and in the setting of refractory cardiac arrest. The present review aims to provide an update on the recent literature evaluating the evolving role of temporary MCS devices, and to provide insights int...
Source: Current Opinion in Cardiology - June 10, 2021 Category: Cardiology Tags: CLINICAL TRIALS: Edited by Neal S. Kleiman Source Type: research
Editorial introductions
No abstract available (Source: Current Opinion in Cardiology)
Source: Current Opinion in Cardiology - June 10, 2021 Category: Cardiology Tags: EDITORIAL INTRODUCTIONS Source Type: research
Coronavirus disease 2019: a comprehensive review and meta-analysis on cardiovascular biomarkers
In this study, we conducted a systematic review and meta-analysis, focusing on the association between COVID-19 severity and cardiac-specific biomarkers, including N-terminal pro-B-type natriuretic peptide (NT-proBNP), troponin T (TnT)/troponin I (TnI), lactate dehydrogenase (LDH), creatine kinase, and creatine kinase isoenzyme (CK-MB). TnT had the highest odds ratio or OR (11.83) indicating the greatest association with COVID-19 severity, followed by NT-proBNP (7.57), TnI (6.32), LDH (4.79), D-dimer (4.10), creatine kinase (3.43), and CK-MB (3.35). All of the biomarkers studied were significantly correlated with COVID-19 ...
Source: Current Opinion in Cardiology - April 16, 2021 Category: Cardiology Tags: CARDIAC FAILURE: Edited by Rebecca Cogswell and Gene Kim Source Type: research
